McKesson agreed to acquire Precision Medicine Group for about $2.25 billion in an all-cash transaction, aiming to deepen clinical research and biopharma commercialization capabilities. The deal combines Precision’s biomarker intelligence, lab services, and market access consulting with McKesson’s healthcare distribution and oncology assets. McKesson said Precision will be folded into its Oncology & Multispecialty segment after closing, pending regulatory approvals. The company framed the acquisition as an end-to-end bridge from clinical trial execution to patient delivery. The transaction underscores continued consolidation among service providers supporting biotech drug development lifecycles.